1800-272-662
Shopping Cart 0
countryflagAU
Login

Repligen Corporation

Healthcare US RGEN

121.79USD
-6.1(4.77%)

Last update at 2026-03-10T20:00:00Z

Day Range

121.54129.00
LowHigh

52 Week Range

110.45211.13
LowHigh

Fundamentals

  • Previous Close 127.89
  • Market Cap8758.55M
  • Volume1155908
  • P/E Ratio580.56
  • Dividend Yield-%
  • EBITDA95.37M
  • Revenue TTM607.45M
  • Revenue Per Share TTM10.89
  • Gross Profit TTM 455.71M
  • Diluted EPS TTM0.27

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 219.14M 153.54M 59.22M 26.15M 21.44M
Minority interest - - - - -
Net income 185.96M 128.29M 59.93M 21.41M 16.62M
Selling general administrative 215.83M 183.87M 119.62M 95.61M 65.69M
Selling and marketing expenses - - - - 0.63M
Gross profit 455.71M 391.25M 209.63M 151.15M 108.08M
Reconciled depreciation 50.98M 38.45M 27.07M 20.87M 15.78M
Ebit 133.61M 133.50M 42.54M 14.90M 10.47M
Ebitda 184.59M 171.95M 69.61M 35.77M 26.25M
Depreciation and amortization 50.98M 38.45M 27.07M 20.87M 15.78M
Non operating income net other -4.36800M -0.99200M 1.53M -0.64000M 2.16M
Operating income 133.61M 133.50M 42.54M 14.90M 25.99M
Other operating expenses 605.60M 497.42M 296.44M 234.16M 168.04M
Interest expense 1.16M 12.71M 12.13M 9.29M 6.71M
Tax provision 33.18M 25.25M -0.70900M 4.74M 4.82M
Interest income - - - 3.97M 4.81M
Net interest income -2.97700M -12.71400M -12.13300M -9.29200M -6.70900M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 33.18M 25.25M -0.70900M 4.74M 4.82M
Total revenue 801.54M 670.53M 366.26M 270.25M 194.03M
Total operating expenses 259.76M 218.14M 139.80M 115.06M 82.09M
Cost of revenue 345.83M 279.28M 156.63M 119.10M 85.95M
Total other income expense net 85.53M 20.04M 16.68M 11.25M 2.16M
Discontinued operations - - - - -
Net income from continuing ops 185.96M 128.29M 59.93M 21.41M 16.62M
Net income applicable to common shares 185.96M 128.29M 59.93M 21.41M 16.62M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 2824.41M 2524.66M 2358.35M 1902.89M 1400.11M
Intangible assets 400.49M 353.68M 337.27M 287.10M 212.55M
Earning assets - - - - -
Other current assets 33.24M 17.41M 19.27M 14.09M 3.12M
Total liab 853.21M 613.96M 608.29M 373.74M 340.35M
Total stockholder equity 1971.20M 397.27M 1750.07M 65.77M 5.84M
Deferred long term liab - 23.00M 33.48M 27.03M 29.94M
Other current liab 53.23M 65.79M 60.65M 37.77M 28.33M
Common stock 0.56M 0.56M 0.55M 0.55M 0.52M
Capital stock 0.56M 0.56M 0.55M 0.55M 0.52M
Retained earnings 438.85M 397.27M 194.06M 65.77M 5.84M
Other liab - 78.37M 130.53M 28.36M 32.27M
Good will 987.12M 855.51M 860.36M 618.30M 468.41M
Other assets - 1.66M 2.52M 28.23M 3.16M
Cash 751.32M 523.46M 603.81M 717.29M 528.39M
Cash and equivalents - - - - -
Total current liabilities 158.16M 404.20M 375.26M 318.96M 48.31M
Current deferred revenue 10.29M 19.28M 14.85M 15.32M 5.00M
Net debt -39.51900M -100.49700M -237.76100M -441.87600M -265.07300M
Short term debt 75.08M 291.57M 263.56M 248.99M 3.56M
Short long term debt 69.45M 284.62M 255.26M 243.74M -
Short long term debt total 711.80M 422.96M 366.05M 275.42M 263.32M
Other stockholder equity 1569.23M 33.84M 1572.34M -2.63300M 14.51M
Property plant equipment - 190.67M 124.96M 66.87M 48.45M
Total current assets 1111.04M 998.12M 931.68M 902.38M 641.83M
Long term investments - - - - -
Net tangible assets - 701.51M 552.43M 623.75M 378.80M
Short term investments 0.00000M 100.30M - - -
Net receivables 124.16M 116.25M 117.42M 71.39M 43.67M
Long term debt 510.14M - - - 232.77M
Inventory 202.32M 238.28M 184.49M 95.03M 54.83M
Accounts payable 19.56M 27.55M 36.20M 16.88M 11.43M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -37.43100M -34.39400M -16.88600M 2.08M -15.02700M
Additional paid in capital - - - - -
Common stock total equity - 0.56M 0.55M 0.55M 0.52M
Preferred stock total equity - - - - -
Retained earnings total equity - 397.27M 194.06M 65.77M 5.84M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.28M 0.81M 0.61M 0.57M 0.24M
Deferred long term asset charges - - - 2.48M 2.92M
Non current assets total 1713.37M 1526.54M 1426.68M 1000.50M 758.28M
Capital lease obligations 132.21M 138.35M 110.80M 31.68M 30.55M
Long term debt total - - - - 232.77M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -74.67800M -100.00000M -221.16900M -201.38500M -205.30800M
Change to liabilities - -9.25000M 41.30M 4.61M 13.74M
Total cashflows from investing activities - -233.23600M -221.16900M -201.38500M -205.30800M
Net borrowings - -0.02600M -0.02100M -0.02100M 163.48M
Total cash from financing activities 248.96M -13.33700M 0.96M 305.92M 484.87M
Change to operating activities - 5.19M 14.65M -1.38600M 13.20M
Net income 41.58M 185.96M 128.29M 59.93M 21.41M
Change in cash 227.87M -80.35600M -113.47800M 179.88M 343.58M
Begin period cash flow 523.46M 603.81M 717.29M 537.41M 193.82M
End period cash flow 751.32M 523.46M 603.81M 717.29M 537.41M
Total cash from operating activities 113.92M 172.08M 119.02M 62.62M 67.22M
Issuance of capital stock - 0.00000M 0.00000M 297.77M 320.71M
Depreciation 68.08M 50.98M 38.45M 27.07M 20.87M
Other cashflows from investing activities - -48.40200M -154.08000M -178.93000M -4.65000M
Dividends paid 565.68M 17.02M 2.90M - 0.49M
Change to inventory 40.97M -57.20400M -89.78100M -29.26000M -9.31400M
Change to account receivables -3.31200M -3.59600M -46.52300M -21.02000M -7.72600M
Sale purchase of stock -14.38600M -17.01800M -2.89700M -0.01000M -0.49000M
Other cashflows from financing activities -20.57000M 17.02M -76.19200M 8.15M 280.12M
Change to netincome - 25.86M 34.88M 13.28M 18.54M
Capital expenditures 38.99M 133.35M 71.28M 26.34M 23.15M
Change receivables - -3.59600M -46.52300M -20.89200M -7.83000M
Cash flows other operating - -22.49000M 0.88M -3.07600M 2.27M
Exchange rate changes - - -12.28600M 12.73M -3.19000M
Cash and cash equivalents changes - -74.49000M -113.47800M 179.88M 343.58M
Change in working capital -8.63700M -63.81100M -102.12800M -48.62000M -1.13500M
Stock based compensation 25.57M 27.32M 27.50M 17.01M 12.85M
Other non cash items -14.99900M -27.01400M 20.39M 11.24M 13.85M
Free cash flow 74.93M 38.74M 47.74M 36.28M 44.06M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
RGEN
Repligen Corporation		 -6.1 4.77% 121.79 580.56 119.05 14.99 4.86 14.94 71.12
ISRG
Intuitive Surgical Inc		 -7.71 1.56% 485.85 73.05 61.73 19.15 10.25 18.41 59.92
ESLOY
Essilor International SA		 -0.25 0.20% 122.50 35.39 24.81 3.63 2.20 4.00 16.25
ESLOF
EssilorLuxottica Société anonyme		 4.90 2.00% 249.71 35.71 25.13 3.62 2.23 4.00 16.25
BDX
Becton Dickinson and Company		 -1.58 0.95% 163.88 37.72 15.92 3.25 2.49 4.08 17.10

Reports Covered

Stock Research & News

View All

Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Repligen Corporation

Building 1, Waltham, MA, United States, 02453

Key Executives

Name Title Year Born
Mr. Anthony J. Hunt Pres, CEO & Director 1964
Mr. Jon K. Snodgres Chief Financial Officer 1966
Mr. James R. Bylund Chief Operating Officer 1964
Ms. Christine Gebski Sr. VP of Filtration & Chromatography 1969
Mr. Ralf Kuriyel Sr. VP of R&D 1959
Ms. Sondra S. Newman Global Head of Investor Relations NA
Ms. Kimberly Cornwell Global Head of Legal & Gen. Counsel NA
Mr. Stephen Tingley VP & Head of Global Sales NA
Ms. Rachel Goodrich VP of Marketing NA
Mr. Craig Harrison Sr. VP of Process Analytics NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.